B7-H1 Antigen

Home
About
Help
History (1)
- B7-H1 Antigen
- See All Pages

"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.

Descriptor ID	D060890
MeSH Number(s)	D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
Concept/Terms	B7-H1 Antigen B7-H1 Antigen Antigen, B7-H1 B7 H1 Antigen Programmed Cell Death 1 Ligand 1 B7-H1 Immune Costimulatory Protein B7 H1 Immune Costimulatory Protein PD-L1 Costimulatory Protein Costimulatory Protein, PD-L1 PD L1 Costimulatory Protein Programmed Cell Death 1 Ligand 1 Protein CD274 Antigen Antigen, CD274 Antigens, CD274 CD274 Antigens B7H1 Immune Costimulatory Protein

Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
B7 Antigens [D12.776.467.150]
B7-H1 Antigen [D12.776.467.150.300]
Membrane Proteins [D12.776.543]
B7 Antigens [D12.776.543.095]
B7-H1 Antigen [D12.776.543.095.300]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
B7 Antigens [D23.050.301.285]
B7-H1 Antigen [D23.050.301.285.400]
Intercellular Signaling Peptides and Proteins [D23.529]
B7 Antigens [D23.529.168]
B7-H1 Antigen [D23.529.168.300]

Below are MeSH descriptors whose meaning is related to "B7-H1 Antigen".

Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.

Bar chart showing 31 publications over 13 distinct years, with a maximum of 6 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2011	0	2	2
2013	1	0	1
2014	0	1	1
2015	1	2	3
2016	5	1	6
2017	1	1	2
2018	2	0	2
2019	1	0	1
2020	1	3	4
2021	1	1	2
2022	2	1	3
2023	0	3	3

Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.

Dora D, Ligeti B, Kovacs T, Revisnyei P, Galffy G, Dulka E, Krizs?n D, Kalcsevszki R, Megyesfalvi Z, Dome B, Weiss GJ, Lohinai Z. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. Oncoimmunology. 2023; 12(1):2204746.

View in: PubMed
Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023 05 03; 15(694):eade5855.

View in: PubMed
Zantut-Wittmann DE, Barreto IS, Laus AC, Moreno DA, Moma CA, Maia FFR, Assump??o LVMD, Reis RM. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma. Mol Cell Endocrinol. 2023 06 15; 570:111931.

View in: PubMed
Varlotto JM, Sun Z, Ky B, Upshaw J, Fitzgerald TJ, Diehn M, Lovly C, Belani C, Oettel K, Masters G, Harkenrider M, Ross H, Ramalingam S, Pennell NA. A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clin Lung Cancer. 2022 Nov; 23(7):547-560.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Massari F. Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a?meta-analysis. Immunotherapy. 2022 06; 14(8):617-625.

View in: PubMed
Wang M, Xiong C, Mercurio AM. PD-LI promotes rear retraction during persistent cell migration by altering integrin ?4 dynamics. J Cell Biol. 2022 05 02; 221(5).

View in: PubMed
Ho TH, Pfeffer K, Weiss GJ, Ruiz Y, Lake DF. Identification of a CD4+ T cell line with Treg-like activity. Hum Immunol. 2022 Apr; 83(4):281-294.

View in: PubMed
Di Tinco R, Bertani G, Pisciotta A, Bertoni L, Pignatti E, Maccaferri M, Bertacchini J, Sena P, Vallarola A, Tupler R, Croci S, Bonacini M, Salvarani C, Carnevale G. Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. Stem Cell Res Ther. 2021 12 04; 12(1):598.

View in: PubMed
Kummer MP, Ising C, Kummer C, Sarlus H, Griep A, Vieira-Saecker A, Schwartz S, Halle A, Br?ckner M, H?ndler K, Schultze JL, Beyer M, Latz E, Heneka MT. Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. EMBO J. 2021 12 15; 40(24):e108662.

View in: PubMed
Mulvaney PM, Massey PR, Yu KK, Drinan JE, Schmults CD. Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2021 09; 141(9):2161-2169.

View in: PubMed

People

Explore

Similar Concepts

Top Journals